Actinium Pharmaceuticals Reports Improved Q2 Loss of $6.9 Million, Focuses on Targeted Radiotherapies

Actinium Pharmaceuticals, Inc. reported its financial results for the second quarter and first half of 2025, revealing a net loss of $6.9 million for the three months ending June 30, 2025, a significant improvement from a net loss of $11.4 million during the same period in 2024. For the first half of 2025, the company recorded a net loss of $22.8 million, compared to a loss of $20.0 million in the prior year. The company did not generate any revenue during both the three and six months ended June 30, 2025, consistent with the previous year. Operating expenses for the second quarter decreased to $7.5 million from $12.4 million in 2024, primarily due to reduced research and development costs and lower general and administrative expenses.

Actinium's total operating expenses for the first half of 2025 were $24.1 million, up from $22.0 million in the same period of 2024. The increase was largely attributed to a rise in general and administrative expenses, which reached $11.6 million, compared to $6.6 million in the prior year, driven by higher non-cash stock-based compensation expenses. Research and development expenses also decreased to $12.6 million from $15.5 million, reflecting a reduction in headcount and lower clinical activity related to its Iomab-B program.

The company’s cash and cash equivalents stood at $59.9 million as of June 30, 2025, down from $72.9 million at the end of 2024. Actinium's total assets decreased to $63.0 million from $76.9 million at the end of the previous fiscal year. The company’s liabilities remained relatively stable, totaling $44.0 million, compared to $44.1 million at the end of 2024. Actinium's stockholders' equity decreased to $19.0 million from $32.8 million, primarily due to the accumulated deficit, which increased to $398.6 million.

Strategically, Actinium is focusing on advancing its pipeline of targeted radiotherapies, including Actimab-A and ATNM-400, which are aimed at treating various cancers. The company is also seeking to partner or out-license its Iomab-B program, which has shown promise in clinical trials but requires further studies to meet FDA requirements for approval. Actinium has initiated a Phase 2/3 trial for Iomab-B and is actively enrolling patients in its Iomab-ACT trial, which aims to improve patient access to CAR-T therapies.

Looking ahead, Actinium anticipates that its existing resources will be sufficient to fund operations for more than 12 months following the report date. The company is also evaluating potential strategic partnerships to enhance its development efforts and expand its market presence in the competitive biopharmaceutical landscape.